Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Plasmacytoma

ClinicalTrials.gov lists 30 trials for Plasmacytoma or a narrower condition beneath it.

MeSH D010954 Neoplasms Neoplasm C04 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 8 Phase 1/2 Phase 1/2 5 Phase 2 Phase 2 9 Phase 3 Phase 3 2 Not applicable Not applicable 2 Observational Observational 4 Phase 1 Phase 1 8 Phase 1/2 Phase 1/2 5 Phase 2 Phase 2 9 Phase 3 Phase 3 2 Not applicable Not applicable 2 Observational Observational 4

Trials per phase

30 of the 30 trials are tagged with Plasmacytoma itself; the rest are tagged with a narrower condition beneath it.

Get the Plasmacytoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Plasmacytoma trials start? (17)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 3
  • Not applicable
  • Observational

Top of scale: 3

1998: 1 trials (Phase 1/2 1) 2000: 1 trials (Phase 2 1) 2002: 1 trials (Phase 1 1) 2005: 2 trials (Not applicable 1, Phase 2 1) 2007: 1 trials (Phase 1/2 1) 2009: 2 trials (Observational 1, Phase 1/2 1) 2010: 2 trials (Phase 1 2) 2013: 1 trials (Observational 1) 2014: 3 trials (Phase 3 1, Phase 2 1, Phase 1 1) 2015: 2 trials (Phase 2 2) 2016: 2 trials (Observational 1, Phase 1 1) 2017: 2 trials (Phase 3 1, Phase 2 1) 2018: 2 trials (Observational 1, Phase 1 1) 2019: 3 trials (Phase 2 3) 2020: 1 trials (Not applicable 1) 2022: 1 trials (Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 2
2022 1
2020 1
2019 3
2018 2
2017 2
2016 2
2015 2
2014 3
2013 1

Showing 10 of 17 earlier years.

Start your 14-day trial Email me all 17 earlier years as a PDF

No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Plasmacytoma trials in? (6)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 8
Phase 1/2 5
Phase 2 9
Phase 3 2
Not applicable 2
Observational 4

How many Plasmacytoma trials are recruiting? (6)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 3
Recruiting 1
Active, not recruiting 2
Completed 15
Terminated 4

Showing 5 of 6 statuses.

Start your 14-day trial Email me all 6 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Plasmacytoma trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Array Biopharma, now a wholly owned subsidiary of Pfizer 1
Celgene 1
Cylene Pharmaceuticals 1
Gilead Sciences 1
Hebei Senlang Biotechnology Inc., Ltd. 1

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Plasmacytoma? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
IXAZOMIB 2
POMALIDOMIDE 2

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 6
X: Lenalidomide 4
Dexamethasone, steroid; oral 2
ARRY-520, KSP(Eg5) inhibitor; intravenous 2
Bortezomib SC 2

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Plasmacytoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 80 2
Febrile neutropenia 21 4
Pyrexia 19 2
Bronchitis 13 2
Sepsis 13 2

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Plasmacytoma? (25)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Rapidly Enlarging Parotid Mass in a Person Living with HIV: A Case of Multiple Myeloma with Extramedullary Plasmacytoma. The American journal of case reports 2023 Yes
Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA. Leukemia research 2022 Yes
Radiotherapy Alone is Associated with Improved Outcomes Over Surgery in the Management of Solitary Plasmacytoma. Asian Pacific journal of cancer prevention : APJCP 2015 Yes
Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. International journal of radiation oncology, biology, physics 2006 Yes
Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 2006 Yes

Showing 5 of 25 publications.

Start your 14-day trial Email me all 25 publications as a PDF

Prevalence (6)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Plasmacytoma Annual incidence 1-9 / 1 000 000 United States US Exact
Plasmacytoma Annual incidence 1-9 / 1 000 000 United States US Unspecified
Plasmacytoma Annual incidence 1-9 / 1 000 000 United States US Exact
Plasmacytoma Point prevalence Unknown Worldwide Not stated Unspecified
Plasmacytoma Point prevalence Unknown Worldwide Not stated Exact

Showing 5 of 6 prevalence observations.

Start your 14-day trial Email me all 6 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Plasmacytoma 86855 Exact Orphanet Rare Disease Ontology (ORDO)
Plasmacytoma 86855 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages